60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.00 and traded as high as $1.02. 60 Degrees Pharmaceuticals shares last traded at $1.01, with a volume of 71,686 shares traded.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.85.
Read Our Latest Report on 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Stock Up 11.5%
The firm has a market cap of $3.56 million, a P/E ratio of -0.21 and a beta of 2.47. The firm has a fifty day moving average of $1.00 and a 200-day moving average of $1.77.
60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.16). The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.20 million. On average, equities analysts forecast that 60 Degrees Pharmaceuticals Inc. will post -3.31 EPS for the current year.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent.
Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.
Featured Stories
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
